

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: BM1/22 - Bone Markers

Deadline: 15.04.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(431) Parathyroid hormone (PTH)					29							28	27	96%
Samples and groups	[pmol/L]													
Sample A		7,34	2,0	27	29							28	27	96%
(60) Roche		6,46	0,57	8,9	17	0	CVPG	6,52	0,19	23%	5,02	8,02	17	
(179) Siemens		8,88	0,21	2,4	5	0	CVPG	9,19	0,53	23%	7,07	11,4	5	
Other					7	1							6	
								4x 1, 2x 12, 1x 29						
Sample B		23,8	7,0	29	29							28	27	96%
(60) Roche		21,5	1,8	8,1	17	0	CVPG	21,6	0,57	23%	16,6	26,6	17	
(179) Siemens		29,5	2,1	7,1	5	0	CVPG	29,4	1,9	23%	22,6	36,2	5	
Other					7	0							6	
								4x 1, 2x 12, 1x 29						
(432) Collagen telopeptide CTx-beta					20							19	18	95%
Samples and groups	[ng/L]													
Sample A		288	22	7,5	20							19	18	95%
(60) Roche		290	20	6,8	19	0	CVPG	290	4,5	17%	240	340	19	
Other					1	0							0	
								1x 183						
Sample B		678	65	9,6	20							19	18	95%
(60) Roche		684	60	8,7	19	0	CVPG	688	12	17%	571	805	19	
Other					1	0							0	
								1x 183						
(433) P1NP					15							15	14	93%
Samples and groups	[µg/L]													
Sample A		34,2	2,8	8,1	15							15	14	93%
(60) Roche		34,2	2,8	8,1	15	1	CVPG	33,7	0,66	20%	26,9	40,5	15	
Sample B		210	17	8,3	15							15	15	100%
(60) Roche		210	17	8,3	15	0	CVPG	206	4,1	20%	164	248	15	
(434) Osteocalcin					19							17	15	88%
Samples and groups	[µg/L]													
Sample A		18,0	1,1	5,9	19							17	16	94%
(60) Roche		18,2	0,99	5,4	17	0	CVPG	18,4	0,24	13%	16	20,8	17	
Other					2	0							0	
								1x 24, 1x 164						
Sample B		91,8	7,4	8,1	19							17	15	88%
(60) Roche		91,9	6,1	6,6	17	0	CVPG	92,9	1,3	13%	80,8	105	17	
Other					2	0							0	
								1x 24, 1x 164						
(435) 25-hydroxyvitamin D					30							29	27	93%
Samples and groups	[nmol/L]													
Sample A		80,0	19	23	30							29	28	97%
(1) Abbott		58,3	4,0	6,9	5	0	CVPG	60,2	1,4	33%	40,3	80,1	5	
(60) Roche		84,5	13	15	20	0	CVPG	79,7	4,1	33%	53,3	106	20	
Other					5	0							4	
								2x 12, 2x 179, 1x 998						
Sample B		166	33	20	30							29	28	97%
(1) Abbott		133	2,2	1,7	5	0	CVPG	134	1,9	33%	89,7	179	5	
(60) Roche		172	26	15	20	0	CVPG	161	7,6	33%	107	215	20	
Other					5	0							4	
								2x 12, 2x 179, 1x 998						

st_kn_p

End of report

Printed: 22.04.2022